Positive News Coverage Somewhat Unlikely to Impact BioSpecifics Technologies (BSTC) Stock Price

Media coverage about BioSpecifics Technologies (NASDAQ:BSTC) has been trending positive recently, Accern reports. Accern rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioSpecifics Technologies earned a daily sentiment score of 0.34 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.899685555857 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the media stories that may have effected Accern Sentiment’s scoring:

Shares of BSTC stock traded up $0.73 during mid-day trading on Wednesday, reaching $43.40. 21,646 shares of the company’s stock were exchanged, compared to its average volume of 29,206. The company has a market cap of $307.48, a price-to-earnings ratio of 28.00 and a beta of 1.55. BioSpecifics Technologies has a fifty-two week low of $38.05 and a fifty-two week high of $58.79.

BSTC has been the topic of a number of recent analyst reports. HC Wainwright restated a “buy” rating on shares of BioSpecifics Technologies in a research report on Monday, December 11th. Zacks Investment Research upgraded shares of BioSpecifics Technologies from a “sell” rating to a “hold” rating and set a $49.00 price objective for the company in a research note on Thursday, December 28th.

COPYRIGHT VIOLATION NOTICE: This news story was first published by BBNS and is the sole property of of BBNS. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://baseballnewssource.com/2018/03/21/biospecifics-technologies-bstc-earning-favorable-press-coverage-analysis-finds/1923454.html.

BioSpecifics Technologies Company Profile

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.

Insider Buying and Selling by Quarter for BioSpecifics Technologies (NASDAQ:BSTC)

Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Tampa Bay Starting Relievers In Place of Starters
Tampa Bay Starting Relievers In Place of Starters
Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old


Leave a Reply

 
© 2006-2018 BBNS.